Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Karolinska Development AB ( (SE:KDEV) ) has shared an announcement.
Karolinska Development’s portfolio company, BOOST Pharma, has announced promising long-term results from its BOOSTB4 phase 1/2 trial for BT-101, a cell-based therapy targeting Osteogenesis imperfecta. The data, presented at an international conference, shows a significant reduction in bone fractures among treated patients, indicating BT-101’s potential as a disease-modifying treatment in an area with high medical need and no adequate existing treatments.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region. The company invests in developing these innovations into commercial products that aim to improve patients’ lives and provide attractive returns to shareholders. With access to world-class medical innovations at the Karolinska Institutet and other leading research institutes, Karolinska Development supports the growth of companies targeting innovative treatments for life-threatening or serious debilitating diseases.
Average Trading Volume: 284,420
Current Market Cap: SEK233.9M
For detailed information about KDEV stock, go to TipRanks’ Stock Analysis page.